Definium Therapeutics, Inc.
DFTX
Positions held
Your positionsDFTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Definium Therapeutics operates in the biotechnology sector, which is known for its potential high returns due to innovation and breakthroughs in healthcare.
- The company's market cap stands at approximately $4.79 billion, indicating a significant valuation in the biotech space.
- Definium's target mean price is $71.65, suggesting a potential upside from current levels.
- Definium Therapeutics has reported zero revenue for multiple quarters, indicating a lack of commercial viability.
- The company has a net income of -158.986 million for Q2 2026, reflecting ongoing financial losses.
- Definium has a 'Strong Sell' score of -26.00, with several bearish indicators such as a declining RSI and MACD.
Fundamentals
| Market cap | $4.59B | Enterprise value | $3.55B | Trailing P/E | — | Forward P/E | -17.97 |
| PEG | — | Price / book | 5.00 | Beta | 2.19 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -64.1% | ROA | -20.6% | Debt / equity | 0.04 |
| Current ratio | 6.95 | Free cash flow | $7.61M | Analyst recommendation | none | Mean target | $71.65 |
| 52w high | $49.70 | 52w low | $10.47 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$159M | -$77.1M | -$50.4M | -$67.3M | -$42.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$75.1M | -$59.2M | -$47.6M | -$45.7M | -$40.9M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$184M | -$109M | -$95.7M | -$56.8M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$166M | -$104M | -$93.9M | -$66.3M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-30 · Jefferies Highlights Three Biotech Stocks With Blockbuster Potential
2026-09-30 · Definium Therapeutics Insider Sold Shares Worth $1,153,784, According to a Recent SEC Filing
2026-09-28 · Definium Therapeutics Announces New Employee Inducement Grants
2026-09-24 · Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression
2026-09-21 · Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-09-20 · Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching
2026-09-19 · Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study
2026-09-16 · Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
2026-09-15 · Definium Reports Second Phase III Success in Anxiety Disorder Program
2026-09-15 · Definium Therapeutics (DFTX) Stock May Trade At A Premium Despite Phase 3 DT120 Results
2026-09-15 · Definium tees up regulatory submission for psychedelic on Phase III hat trick
2026-09-15 · Definium tees up regulatory submission for psychedelic on Phase III hat trick
Price (daily)
Full chart · RSI · MACD · patterns